Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer

@article{Brand2014NuclearEG,
  title={Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer},
  author={T. Brand and M. Iida and E. F. Dunn and Neha Luthar and Kellie T. Kostopoulos and Kelsey L Corrigan and Matthew J Wleklinski and D. Yang and K. Wisinski and R. Salgia and D. L. Wheeler},
  journal={Molecular Cancer Therapeutics},
  year={2014},
  volume={13},
  pages={1356 - 1368}
}
  • T. Brand, M. Iida, +8 authors D. L. Wheeler
  • Published 2014
  • Biology, Medicine
  • Molecular Cancer Therapeutics
  • Triple-negative breast cancer (TNBC) is a subclass of breast cancers (i.e., estrogen receptor–negative, progesterone receptor–negative, and HER2-negative) that have poor prognosis and very few identified molecular targets. Strikingly, a high percentage of TNBCs overexpresses the EGF receptor (EGFR), yet EGFR inhibition has yielded little clinical benefit. Over the last decade, advances in EGFR biology have established that EGFR functions in two distinct signaling pathways: (i) classical… CONTINUE READING
    40 Citations
    The paradoxical functions of EGFR during breast cancer progression
    • 41
    BAG 3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer
    • Highly Influenced
    BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer
    • 3
    • Highly Influenced
    • PDF
    Canonical ErbB-2 isoform and ErbB-2 variant c located in the nucleus drive triple negative breast cancer growth
    Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer
    • 1
    • Highly Influenced
    • PDF

    References

    SHOWING 1-10 OF 46 REFERENCES
    Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
    • 268
    Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR
    • 89
    • PDF
    Src: a potential target for the treatment of triple-negative breast cancer.
    • 108
    Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer.
    • 267
    • PDF
    The nuclear epidermal growth factor receptor signaling network and its role in cancer.
    • 181
    Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
    • 31
    Nuclear EGFR contributes to acquired resistance to cetuximab
    • 265
    • PDF
    Nuclear EGFR in ductal invasive breast cancer: correlation with cyclin-D1 and prognosis
    • 76
    • PDF
    Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations.
    • 195